Collaboration with Merck KGaA, Darmstadt, Germany to evaluate eftilagimod alpha in combination with bintrafusp alfa
New investigator-initiated explorative, multi-centre, open-labelled Phase I/IIa trial in 12 previously treated patients with different solid tumours, called INSIGHT-005
First patient is expected to be enrolled and dosed in H2 of calendar year 2021
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.